Valerie Carnes, NP
Gerontology · la Junta, CONPI 1992108716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Amgen at 28.2% of the total.
Across 36 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$183
- Novo Nordisk$90
- Lilly USA, LLC$77
- AbbVie$58
- Xeris Pharmaceuticals, Inc.$43
- AstraZeneca$35
- plus $162 from 9 others
What the payments were for
- Food & beverage$649100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 10 | $183 |
| Novo Nordisk | 5 | $90 |
| Lilly USA, LLC | 4 | $77 |
| AbbVie | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $43 |
| AstraZeneca | 2 | $35 |
| Viatris Specialty LLC | 1 | $23 |
| Smith+Nephew | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$649 in reported general payments places this provider in the 60th percentile of 85 gerontology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 158 | $191,955 |
| JardianceEmpagliflozin | 112 | $117,983 |
| OzempicSemaglutide | 100 | $100,301 |
| XareltoRivaroxaban | 58 | $65,623 |
| EliquisApixaban | 55 | $59,375 |
| JanuviaSitagliptin Phosphate | 45 | $46,925 |
| TrulicityDulaglutide | 35 | $38,008 |
| VraylarCariprazine Hcl | 25 | $35,500 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $29,578 |
| Advair HfaFluticasone Propion/Salmeterol | 72 | $28,420 |
| SymbicortBudesonide/Formoterol Fumarate | 99 | $26,994 |
| FarxigaDapagliflozin Propanediol | 32 | $26,407 |
| TradjentaLinagliptin | 27 | $22,688 |
| Repatha SureclickEvolocumab | 20 | $16,975 |
| Spiriva HandihalerTiotropium Bromide | 27 | $16,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $77 | $229,963193 claims |
| Novo NordiskOzempic | $90 | $100,301100 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga | $35 | $82,979162 claims |
| AbbVieVraylar, Linzess, Creon, Synthroid | $58 | $54,765121 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $13,77215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 85 gerontology providers in Colorado.
Other gerontology in la Junta
- Kimberly RobertsonColorado Springs$9K
- Melinda McClendonColorado Springs$8K
- Nicole ChiekaColorado Springs$6K
- Ashley ReadLoveland$5K
- Rhiannon SundayColorado Springs$5K
- Kimberly CunninghamAurora$4K
- Andrea DavisGrand Junction$4K
- Molly DavisDenver$3K
- Coral MartinezPueblo$3K
- Julie HinchmanLakewood$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.